The data of both clonogenic (Fig 4) and MTT (Fig 5) assays demonstrate significantly stronger cancer cell radiosensitization in the case of combining the Hsp90 activity inhibitors with the Hsp induction inhibitors such as quercetin, KNK437, triptolide or NZ28. The gene discussed is HSP90B2P; the disease is cancer.